CC BY 4.0 · TH Open 2021; 05(02): e183-e187
DOI: 10.1055/s-0041-1730036
Original Article

Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature

Shadan Lalezari
1  National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
,
Assaf A. Barg
1  National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
2  Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3  Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel
,
Rima Dardik
1  National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
,
Jacob Luboshitz
1  National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
,
Dalia Bashari
1  National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
,
Einat Avishai
1  National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
,
Gili Kenet
1  National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
2  Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3  Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel
› Author Affiliations

Abstract

Aim Very little is known regarding reproductive choices, pregnancy, and delivery of women with moderate to severe hemophilia. Our aim was to describe our experience with three hemophiliac women and their journey to achieve motherhood.

Methods Medical charts of women with moderate to severe hemophilia A treated at our center were evaluated. Data regarding choices of conception, pregnancy course, mode of delivery, and pregnancy outcomes were obtained.

Results Three women are presented. Whereas patient 1 chose to adopt her first child and later had twins through egg donations and a surrogate mother, patient 2 underwent spontaneous pregnancy and delivered via cesarean section. Patient 3 preferred in vitro fertilization and preimplantation genetic diagnosis to avoid hemophilia and hemophilia carriership in her offspring.

Conclusion The appropriate means to achieve parenthood for women with moderate to severe hemophilia should be individualized and requires support of a comprehensive multidisciplinary team.

Disclosures

All authors have no competing interests except for: Shadan Lalezari has received honoraria/consultation fees from Bayer, Pfizer, Teva, Takeda, Roche, and PI Healthcare.


Assaf A. Barg has received honoraria for lectures from ROCHE and a grant from Pfizer.


Gili Kenet receives grant and research support from Alnylam, Bayer, BPL, Opko Biologics, Pfizer, and Shire, and honoraria for consultancy/lectures from Alnylam, Bayer, CSL, Opko Biologics, Pfizer, Takeda, and ROCHE.


Author Contributions

All authors made substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work. They drafted the work or revised it critically for important intellectual content. The authors approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved




Publication History

Received: 14 February 2021

Accepted: 06 April 2021

Publication Date:
01 June 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany